Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1: Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection

Transplantation

Volumn 62, Issue 11, 1996, Pages 1693-1696

  Heckl Östreicher, Brigitte ^a   Wosnik, Annette ^a   Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEHRINERT; CD59 ANTIGEN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENTARY DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SWINE; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD59; COMPLEMENT C1 INACTIVATOR PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HUMANS; RECEPTORS, COMPLEMENT; SOLUBILITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030466053     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612150-00032     Document Type: Article

References (15)

1. Auchincloss H Jr. Xenogeneic transplantation. Transplantation 1988; 46: 1.
2. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5: 1296.
3. Chrupcala M, Pomer S, Staehler G, Waldherr R, Kirschfink M. Prolongation of discordant renal xenograft survival by depletion of complement. Comparative effects of systemically administered cobra venom factor and soluble complement receptor type 1 in a guinea pig-to-rat model. Transpl Int 1994; 7: S650.
4. Pruitt SK, Baldwin WM, Marsh HC, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868.
5. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
6. Hack CE, Ogilvies AC, Eisele B, Eerenberg AJM, Wagstaff J, Thijs LG. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993; 19: 19.
7. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a Cl esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91: 393.
8. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177.
9. Langford GA, Yannoutsos N, Cozzi E, et al. Production of pigs transgenic for human decay accelerating factor. Transplant Proc 1994; 26: 1400.
10. Pinkert CA. Transgenic pig models for xenotransplantation. Xeno 1994; 2: 10
11. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
12. Heckl-Östreicher B, Binder R, Kirschfink M. Functional activity of the membrane-associated complement-inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejection. Clin Exp Immunol 1995; 102: 589.
13. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by Cl inhibitor. Transplantation 1993; 56: 1171.
14. Dellinger RP, Zimmermann JL, Straube RC, et al. Results of a phase I trial of soluble complement receptor 1 (TP10) in acute lung injury (ALI). Crit Care Med 1996; 24 (suppl 2): A29.
15. White DJG. Xenografting: past and future. Xeno 1994; 2: 1.